期刊
CANCERS
卷 13, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/cancers13030477
关键词
IL-1-blockade; clinical trials; cancer; immunotherapy; adoptive T cell therapy; chimeric antigen receptor T cells; CAR
类别
资金
- Marie Sklodowska-Curie Program Training Network for the Immunotherapy of Cancer - H2020 Program of the European Union [641549]
- Marie Sklodowska-Curie Program Training Network for Optimizing Adoptive T Cell Therapy of Cancer - H2020 Program of the European Union [641549, 955575]
- Hector foundation
- International Doctoral Program i-Target: Immunotargeting of Cancer - Elite Network of Bavaria
- Melanoma Research Alliance [409510]
- Else Kroner-Fresenius-Stiftung
- German Cancer Aid
- Ernst Jung Stiftung
- LMU Munich's Institutional Strategy LMUexcellent within the framework of the German Excellence Initiative
- Bundesministerium fur Bildung und Forschung Project Oncoattract
- European Research Council [756017]
- German Research Foundation (DFG)
- Fritz-Bender Foundation
- Jose-Carreras Foundation
Interleukin-1 cytokines play a crucial role in inflammation and have implications in cancer research. Clinical trials have shown the potential of IL-1 blockade in cancer treatment, but it may also lead to immune toxicities. Current research focuses on utilizing IL-1 blocking agents to enhance the efficacy and safety of adoptive T cell therapy.
Simple Summary Interleukin-1 cytokines are key proinflammatory cytokines which have been implicated with differing pro- and antitumorigenic properties. Recent years have brought exciting insights and developments in IL-1-targeted therapies. Here, we present an overview of past and present research focusing on the role of IL-1 in cancer, with a special focus on clinical research and on therapeutic implications. With this, we strive to assist scientists in their future research objectives and to highlight possible directions for IL-1-targeting therapies in the coming years. Since its discovery, interleukin-1 has been extensively studied in a wide range of medical fields. Besides carrying out vital physiological functions, it has been implicated with a pivotal role in the progression and spreading of different cancer entities. During the last years, several clinical trials have been conducted, shedding light on the role of IL-1 blocking agents for the treatment of cancer. Additionally, recent developments in the field of immuno-oncology have implicated IL-1-induced signaling cascades as a major driver of severe chimeric antigen receptor T cell-associated toxicities such as cytokine release syndrome and immune effector cell-associated neurotoxicity. In this review, we summarize current clinical trials investigating the role of IL-1 blockade in cancer treatment and elaborate the proposed mechanism of these innovative treatment approaches. Additionally, we highlight cutting-edge developments utilizing IL-1 blocking agents to enhance the safety and efficacy of adoptive T cell therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据